

**CARDIOVASCULAR AND RENAL DRUGS ADVISORY
COMMITTEE
MEETING ROSTER
APRIL 26, 2006
8:00 AM – 12:00 PM
*Anti-Hypertensive Drug Class Labeling Session***

Voting Committee Members:

David L. DeMets, Ph.D.
Steven D. Findlay, M.P.H.
Frederick J. Kaskel, M.D., Ph.D.
Thomas G. Pickering, M.D., D.Phil.
Ronald J. Portman, M.D.
John R. Teerlink, M.D.
Lynn Warner-Stevenson, M.D.

Non-Voting Committee Members:

John F. Neylan, M.D. (Industry Representative)

Non-Voting Guest Speaker:

Stephen W. MacMahon, B.Sc., Ph.D., M.P.H., F.A.C.C.

Non-Voting FDA Participants:

Robert J. Temple, M.D.
Norman L. Stockbridge, M.D., Ph.D.

**FOOD AND DRUG
ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH (CDER)
*Cardiovascular and Renal Drugs Advisory Committee
Meeting
April 26, 2006
Participant List***

**Anti-hypertensive Drug Class Labeling
(8:00 A.M. to 12:00 P.M.)**

Non-Voting Participant:

Guest Speakers

Stephen W. MacMahon, B.Sc., Ph.D., M.P.H., F.A.C.C.
Principal Director
Professor of Cardiovascular Medicine and Epidemiology
The George Institute of International Health
C39 – Royal Prince Alfred Hospital
The University of Sydney
NSW 2006 Australia

FDA Participants

Norman Stockbridge, M.D.
Director
Division of Cardiovascular and Renal
Drug Products
FDA/CDER

Robert Temple, M.D.
Director
Office of Drug Evaluation I (ODEI)
FDA/CDER